Overview

Ebola Vaccines and Drugs Market Overview:

In recent years, Ebola has emerged as one of the world's greatest health threats. Science has known about the Ebola virus and its disease for decades, but the risks of a global epidemic have increased exponentially since globalization. Since West Africa has recently been afflicted by Ebola, the disease has been brought to the forefront of global attention. There are several symptoms associated with Ebola, including sore throat, muscle pain, headache, and fever. The patient suffers from a viral hemorrhagic fever, which means he or she bleeds both internally and externally. By infected patients with the Ebola virus, liver and kidney function is greatly compromised. In the global market for Ebola drugs and vaccines, the lack of a reliable cure for the disease is one of the biggest driving factors, with the need for a cure being among the most urgent and lucrative. Global Ebola drugs and vaccines markets are currently driven by the lack of a foolproof solution. In spite of the development of containment and management protocols for Ebola, a cure has not yet been discovered. There is a massive unmet need for Ebola drugs and vaccines that drives the global market for them. Government support for Ebola research has made developing Ebola drugs and vaccines a profitable business for pharmaceutical companies as well. A major driver for the market in the coming years is also expected to be this factor. Research efforts have also been spurred by the unpredictable nature of Ebola since the risk of disease increases significantly without a clear understanding of its etiology and pathophysiology. In addition to medical factors, traveling between countries with more and more people is one of the most important non-medical factors affecting the global Ebola drug and vaccines market.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Ebola Vaccines and Drugs Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Ebola Vaccines and Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Ebola Vaccines and Drugs Market:

• Arbutus Biopharma
• GlaxoSmithKline
• Johnson & Johnson Services, Inc.
• Hemispherx Biopharma, Inc.
• BioCryst Pharmaceuticals, Inc.
• NanoViricides, Inc.
• NewLink Genetics Corporation
• Chimerix, Inc.
• Sarepta Therapeutics
• Mapp Biopharmaceutical, Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

Ebola Vaccines and Drugs Market Segmentation:

By Treatment

• Vaccine (Under Trials)
   o cAd3-Zebov
   o rVSV-Zebov
   o TKMEbola
   o AVI-7537
   o HEB
   o BCRX
   o NNVC
• Drugs (Under Trials)
   o Brincidofovir
   o ZMapp
   o Favipiravir
   o Zoloft
   o Vascor

By End User

• Hospitals
• Ambulatory Surgery Centres
• Specialized Clinics
• Army Camps (Veteran Facilities)  

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Ebola Vaccines and Drugs Market Sample Video:

Competitive Landscape:

• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:

• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:

• To provide with an exhaustive analysis on the Ebola Vaccines and Drugs Market By Treatment, By End User and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:

• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
       1.1 Objectives of the Study 
       1.2 Market Definition 
       1.3 Market Scope 
               1.3.1 Years Considered for the Study
               1.3.2 Market Covered
       1.4 Currency 
       1.5 Limitations 
       1.6 Stakeholders 

 2.  Research Methodology 
       2.1 Research Data 
              2.1.1 Secondary Data
                 2.1.1.1 Key Data from Secondary Sources
              2.1.2 Primary Data
                 2.1.2.1 Key Data from Primary Sources
       2.2 Market Size Estimation 
       2.3 Market Breakdown and Data Triangulation 
       2.4 Assumptions for the Study  

3. Executive Summary
       3.1 Market Outlook
       3.2 Segment Outlook
       3.3 Competitive Insights

4. Ebola Vaccines and Drugs Market Variables, Trends & Scope
       4.1. Market Lineage Outlook
       4.2. Penetration and Growth Prospect Mapping
       4.3. Industry Value Chain Analysis
       4.4. Cost Analysis Breakdown
       4.5. Technology Overview
       4.6. Regulatory Framework
                 4.6.1. Reimbursement Framework
                 4.6.2. Standards and Compliances

5. Market Overview
       5.1. Market Dynamics
                  5.1.1. Market Driver Analysis
                            5.1.1.1. Increasing focus of Ebola Vaccines and Drugs Companies on Brand Protection
                            5.1.1.2. Untapped Opportunities in Emerging Regions
                  5.1.2. Market Restraint Analysis
                            5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
                  5.1.3. Industry Challenges
                            5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Ebola Vaccines and Drugs Market Analysis Tools
       6.1. Industry Analysis - Porter’s
               6.1.1. Supplier Power
               6.1.2. Buyer Power
               6.1.3. Substitution Threat
               6.1.4. Threat from New Entrants
               6.1.5. Competitive Rivalry
       6.2. Pestel Analysis
               6.2.1. Political Landscape
               6.2.2. Environmental Landscape
               6.2.3. Social Landscape
               6.2.4. Technology Landscape
               6.2.5. Legal Landscape
       6.3. Major Deals And Strategic Alliances Analysis
                6.3.1. Joint Ventures
                6.3.2. Mergers and Acquisitions
                6.3.3. Licensing and Partnership
                6.3.4. Technology Collaborations
                6.3.5. Strategic Divestments
       6.4. Market Entry Strategies
       6.5. Case Studies

7. Ebola Vaccines and Drugs Market, By Treatment Historical Analysis and Forecast 2022-2028 (USD Million)
       7.1. Vaccine (Under Trials)
              7.1.1. cAd3-Zebov
              7.1.2. rVSV-Zebov
              7.1.3. TKMEbola
              7.1.4. AVI-7537
              7.1.5. HEB
              7.1.6. BCRX
              7.1.7. NNVC
       7.2. Drugs (Under Trials)
              7.2.1. Brincidofovir
              7.2.2. ZMapp
              7.2.3. Favipiravir
              7.2.4. Zoloft
              7.2.5. Vascor 

8. Ebola Vaccines and Drugs Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million)
       8.1. Hospitals
       8.2. Ambulatory Surgery Centres
       8.3. Specialized Clinics
       8.4. Army Camps (Veteran Facilities)

9.  North America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
       9.1. Introduction
       9.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
            9.2.1. U.S.A
            9.2.2. Canada
            9.2.3. Mexico
       9.3. Market Size (USD Million) Forecast for North America 2022-2028

10. Latin America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
       10.1. Introduction
       10.2. Regional Market Trends
       10.3. Historical Market Size (USD Million) Analysis By Country, 2016-2020
            10.3.1. Brazil
            10.3.2. Venezuela
            10.3.3. Argentina
            10.3.4. Rest of Latin America
       10.4. Market Size (USD Million) Forecast for Latin America 2022-2028

11. Europe Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
       11.1. Introduction
       11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
            11.2.1. Germany
            11.2.2. U.K
            11.2.3. France
            11.2.4. Italy
            11.2.5. Spain
            11.2.6. Russia
            11.2.7. Poland
            11.2.8. Switzerland
            11.2.9. Rest of Western Europe

12. Asia Pacific Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
       12.1. Introduction
       12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
             12.2.1. Japan
             12.2.2. China
             12.2.3. Singapore
             12.2.4. India
             12.2.5. Australia and New Zealand
             12.2.6. ASEAN
             12.2.7. South Korea
             12.2.8. Rest of Asia Pacific
       12.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028

13. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
       13.1. Introduction
       13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
             13.2.1. GCC
             13.2.2. Israel
             13.2.3. South Africa
             13.2.4. Rest of MEA
       13.3. Market Size (USD Million) Forecast for MEA 2022-2028

14. Market Share Analysis and Competitive Landscape   
    14.1. Global Landscape - Key Players, Revenue and Presence
    14.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    14.3. Global Emerging Companies
    14.4. North America - Market Share Analysis and Key Regional Players
    14.5. Europe - Market Share Analysis and Key Regional Players
    14.6. Asia Pacific - Market Share Analysis and Key Regional Players
    14.7. Global Key Player - Growth Matrix

15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Technology Portfolio, Financial Layouts)
       15.1. Arbutus Biopharma
                15.1.1. Company Overview
                15.1.2. Product Portfolio
                15.1.3. SWOT Analysis
                15.1.4. Financial Overview
                15.1.5. Strategic Overview
       15.2. GlaxoSmithKline
                15.2.1. Company Overview
                15.2.2. Product Portfolio
                15.2.3. SWOT Analysis
                15.2.4. Financial Overview
                15.2.5. Strategic Overview
       15.3. Johnson & Johnson Services, Inc.
                15.3.1. Company Overview
                15.3.2. Product Portfolio
                15.3.3. SWOT Analysis
                15.3.4. Financial Overview
                15.3.5. Strategic Overview
       15.4. Hemispherx Biopharma, Inc.
                15.4.1. Company Overview
                15.4.2. Product Portfolio
                15.4.3. SWOT Analysis
                15.4.4. Financial Overview
                15.4.5. Strategic Overview
       15.5. BioCryst Pharmaceuticals, Inc.
                15.5.1. Company Overview
                15.5.2. Product Portfolio
                15.5.3. SWOT Analysis
                15.5.4. Financial Overview
                15.5.5. Strategic Overview
       15.6. NanoViricides, Inc.
                15.6.1. Company Overview
                15.6.2. Product Portfolio
                15.6.3. SWOT Analysis
                15.6.4. Financial Overview
                15.6.5. Strategic Overview
       15.7. NewLink Genetics Corporation
                15.7.1. Company Overview
                15.7.2. Product Portfolio
                15.7.3. SWOT Analysis
                15.7.4. Financial Overview
                15.7.5. Strategic Overview
       15.8. Chimerix, Inc.
                15.8.1. Company Overview
                15.8.2. Product Portfolio
                15.8.3. SWOT Analysis
                15.8.4. Financial Overview
                15.8.5. Strategic Overview
       15.9. Sarepta Therapeutics
                15.9.1. Company Overview
                15.9.2. Product Portfolio
                15.9.3. SWOT Analysis
                15.9.4. Financial Overview
                15.9.5. Strategic Overview
       15.10. Mapp Biopharmaceutical, Inc.
                15.10.1. Company Overview
                15.10.2. Product Portfolio
                15.10.3. SWOT Analysis
                15.10.4. Financial Overview
                15.10.5. Strategic Overview

 16. Pre and Post COVID-19 Impact
    16.1. Positive influence on the healthcare industry
    16.2. The financial disruption of the manufacturing sector
    16.3. Impact of COVID-19 on emerging companies
    16.4. Significant mandates in the healthcare regulations initiated by administrations
    16.5. The overall economic slowdown of the developing and developed nations  
    
17. FutureWise SME key takeaway points for Client

Tables

Figures